Bayer Shares Jump as Supreme Court Agrees to Review Key Roundup Case

Core Viewpoint - Bayer AG's shares increased by 6.41% following the announcement that the Supreme Court will review the Durnell Roundup case, which is significant for the company's ongoing litigation related to its glyphosate-based herbicide Roundup [1][9]. Legal Developments - The Supreme Court's review will address a split among federal circuit courts regarding federal preemption, a key issue in the Roundup litigation [2][9]. - The Solicitor General has supported the review, emphasizing the need to resolve the circuit split and advocating for a ruling in favor of Bayer [3][4]. - The Durnell case resulted in a jury awarding $1.25 million in damages for failure to warn, with Monsanto appealing the verdict [6]. Litigation Status - As of October 15, 2025, Bayer has resolved approximately 132,000 of nearly 197,000 claims related to glyphosate, with a reserve of $7.6 billion set aside for ongoing litigation [10][9]. - Bayer has experienced a mix of outcomes in 28 concluded Roundup-related trials, securing favorable results in 17 cases [8]. Financial Performance - Bayer's shares have surged by 138.5% over the past year, significantly outperforming the industry average of 24.1%, driven by new drug approvals and improved performance in its Crop Science business [11]. - The company has seen strong sales from new products like prostate cancer drug Nubeqa and kidney disease drug Kerendia, which have offset declines in sales from Xarelto [12]. Drug Approvals - Bayer recently received FDA approval for elinzanetant for menopause-related symptoms and accelerated approval for Hyrnuo for lung cancer treatment, which are expected to enhance sales [15][16]. - The expansion of key drugs and the approval of additional products are anticipated to further boost sales in Bayer's pharmaceutical division [18].